A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors

@inproceedings{Lusher1998ARD,
  title={A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors},
  author={Jeanne M. Lusher and Harold Ross Roberts and Geert Davignon and Joist Jh and Heather Smith and Amos Shapiro and Yves Laurian and Kasper Ck and Mannucci Pm},
  year={1998}
}
Recombinant factor VIIa (rFVIIa) was developed to provide an improved procoagulant component capable of ‘by-passing’ inhibitor antibodies in the treatment of haemophilic patients. The primary objective of this study was to compare the efficacy of two dosage regimens of rFVIIa (given intravenously at periodic intervals) in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B with and without inhibitors. The study was designed as a randomized, double… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 41 CITATIONS

Therapeutic Proteins

  • Methods in Molecular Biology™
  • 2005
VIEW 11 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED